TY  - JOUR
AU  - Marques, Miriam
AU  - Tranchant, Robin
AU  - Risa-Ebri, Blanca
AU  - Suarez-Solis, Maria L
AU  - Fernandez, Luis C
AU  - Carrillo-de-Santa-Pau, Enrique
AU  - Del Pozo, Natalia
AU  - Martinez de Villarreal, Jaime
AU  - Meiller, Clement
AU  - Allory, Yves
AU  - Blum, Yuna
AU  - Pirker, Christine
AU  - Hegedus, Balazs
AU  - Barry, Simon T
AU  - Carnero, Amancio
AU  - Berger, Walter
AU  - Jean, Didier
AU  - Real, Francisco X
PY  - 2020
DO  - 10.1158/0008-5472.CAN-19-1633
UR  - http://hdl.handle.net/10668/14929
T2  - Cancer research
AB  - Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid...
LA  - en
PB  - American Association for Cancer Research
KW  - Aniline Compounds
KW  - Benzimidazoles
KW  - Chromones
KW  - Epithelium
KW  - Lung Neoplasms
KW  - Mesothelioma
KW  - Peritoneum
KW  - Pleura
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Proliferation
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Disease Models, Animal
KW  - Female
KW  - Gene Knock-In Techniques
KW  - Humans
KW  - Mesothelioma, Malignant
KW  - Mice
KW  - Mice, Knockout
KW  - Mitogen-Activated Protein Kinase Kinases
KW  - Molecular Targeted Therapy
KW  - PTEN Phosphohydrolase
KW  - Peritoneal Neoplasms
KW  - Pleural Neoplasms
KW  - Primary Cell Culture
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - Tumor Suppressor Protein p53
TI  - Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
TY  - research article
VL  - 80
ER  -